Sepros Limited

Sepros Limited is a Kenyan-based company specializing in the importation and distribution of pharmaceutical products, particularly focusing on animal health and crop science solutions. Established in August 2000 by two veterinarians, the company began with a modest shop in Kiambu Town, aiming to serve the diverse needs of the local farming community. Over the years, Sepros Limited has expanded its operations, offering a broad portfolio of products achieved through partnerships with both local and overseas suppliers. (sepros.co.ke)

The company's mission is to provide distinctive and responsible service, contributing to the country's food security and enhancing the value placed on companion animals and plants. Sepros Limited delivers quality animal health and crop production solutions to resellers, practitioners, producers, and households. Their vision is to become the preferred supplier of these solutions through enhanced customer experience. (sepros.co.ke)

Sepros Limited operates from its main office located at Peflo Centre, Biashara Street, Kiambu Town, Kenya. The company also maintains a retail shop at Kenyatu House, Biashara Street, opposite Equity Bank, Kiambu Town. (sepros.co.ke) While specific details about their warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive partnerships with local and international suppliers suggest a well-established distribution network. This network enables Sepros Limited to effectively serve the Kenyan market, ensuring timely availability and accessibility of their products across the country. (sepros.co.ke)

Sepros Limited plays a significant role in Kenya's pharmaceutical supply chain, primarily acting as a wholesaler and distributor of pharmaceutical products. The company's focus on animal health and crop science solutions positions it as a key player in the agricultural sector, catering to the needs of farmers, veterinary practitioners, and agribusinesses. By sourcing products from both local and international suppliers, Sepros Limited ensures a diverse and reliable supply of pharmaceutical products, contributing to the overall health and productivity of the agricultural community in Kenya. (sepros.co.ke)

Sepros Limited's sourcing strategy exhibits a notable concentration, with a significant portion of its pharmaceutical imports originating from India. This concentration indicates a strategic choice to leverage India's established pharmaceutical manufacturing capabilities, particularly in the production of animal health and crop science products. The company's reliance on a single supplier, Zenex Animal Health India Private Limited, for a substantial number of shipments suggests a stable and long-term partnership. However, this dependency also presents potential risks, such as supply chain disruptions or regulatory changes in India that could impact product availability. To mitigate these risks, Sepros Limited may consider diversifying its supplier base and exploring alternative sourcing options to ensure a resilient supply chain.

The resilience of Sepros Limited's supply chain is closely tied to its sourcing practices. The company's reliance on a single supplier from India for a significant portion of its imports could pose challenges in the event of supply chain disruptions or regulatory changes. To enhance supply chain resilience, Sepros Limited could consider diversifying its supplier base by engaging with additional manufacturers from different countries. This approach would reduce dependency on a single source and provide alternative options in case of unforeseen disruptions. Additionally, ensuring that all suppliers adhere to recognized Good Manufacturing Practices (GMP) and maintaining compliance with Kenyan regulatory standards would further strengthen the supply chain's reliability and product quality.

Sepros Limited's current sourcing pattern, characterized by a high dependency on a single supplier from India, has strategic implications for its competitive position in the Kenyan market. While this approach may offer cost advantages and streamlined logistics, it also exposes the company to risks associated with supply chain disruptions and regulatory changes in the supplier's country. For Indian exporters seeking to become alternative suppliers to Sepros Limited, understanding the company's reliance on a single source presents an opportunity to offer competitive pricing, reliable delivery schedules, and compliance with Kenyan regulatory standards. By addressing these factors, Indian exporters can position themselves as viable alternatives, potentially capturing a share of Sepros Limited's import requirements.

In Kenya, the regulation of pharmaceutical products is overseen by the Pharmacy and Poisons Board (PPB), which operates under the Ministry of Health. The PPB is responsible for ensuring that all pharmaceutical products imported, manufactured, and sold in Kenya meet the required standards of quality, safety, and efficacy. Key legislation governing pharmaceutical imports includes the Pharmacy and Poisons Act (Cap. 244) and the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules. These regulations stipulate that no person shall import, manufacture for sale, or sell any drug in Kenya unless that drug has been registered and listed in accordance with the provisions of these Rules.

Importers of pharmaceutical products into Kenya are required to obtain an import license from the Pharmacy and Poisons Board. This license ensures that the importer complies with all regulatory requirements and that the imported products meet the necessary standards. Additionally, imported pharmaceutical products must adhere to recognized Good Manufacturing Practices (GMP). Certificates of GMP compliance, such as those issued by the World Health Organization (WHO) or the Pharmaceutical Inspection Co-operation Scheme (PIC/S), are essential for the registration and importation of pharmaceutical products into Kenya. Sepros Limited, as an importer, must ensure that its suppliers provide valid GMP certificates to facilitate the smooth importation and distribution of their products.

Imported pharmaceutical products must undergo batch testing to confirm their quality and compliance with Kenyan standards. This process involves submitting samples to recognized laboratories for analysis and obtaining a certificate of analysis, which is a requirement for product registration. Stability requirements ensure that the products maintain their efficacy and safety throughout their shelf life. Labeling requirements include providing clear and accurate information in English and Kiswahili, the official languages of Kenya. This information should include the product name, active ingredients, dosage instructions, and expiry date. Serialization mandates may also be implemented to enhance traceability and prevent counterfeit products from entering the market. Sepros Limited must ensure that all imported products comply with these quality and labeling standards to meet regulatory requirements and maintain consumer trust.

In January 2025, the Pharmacy and Poisons Board issued a public notice warning against the importation and sale of unregistered pharmaceutical products, particularly those referencing the Indian Pharmacopoeia. The notice emphasized that any pharmaceutical product not duly registered by the PPB is strictly prohibited for importation, distribution, sale, or handling in Kenya. This regulatory change underscores the importance of compliance with Kenyan standards and the necessity for importers like Sepros Limited to ensure that all products meet the required registration and quality standards. (pulse.co.ke)

Sepros Limited's focus on animal health and crop science products aligns with the significant demand in Kenya's agricultural sector. The country's reliance on agriculture for economic development and food security drives the need for effective veterinary medicines and crop protection solutions. By importing and distributing these products, Sepros Limited addresses critical needs in the market, supporting farmers and agribusinesses in enhancing productivity and maintaining animal health. The company's partnerships with both local and international suppliers enable it to offer a diverse range of products, catering to various customer requirements and preferences. (sepros.co.ke)

Sepros Limited's sourcing strategy emphasizes the importation of generic pharmaceutical products, particularly those related to animal health and crop science. The company's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a focus on ready-to-use products that meet the immediate needs of the Kenyan market. India's established pharmaceutical manufacturing industry, known for producing high-quality generic medicines, fits well into Sepros Limited's procurement strategy. By sourcing from India, the company leverages cost advantages and a reliable supply chain, ensuring the availability of essential products for its customers. (sepros.co.ke)

Based on its product mix, Sepros Limited primarily serves the agricultural sector in Kenya, including retail pharmacies, veterinary practitioners, and agribusinesses. The company's focus on animal health and crop science solutions positions it as a key supplier of veterinary medicines and crop protection products. By offering a diverse range of products and providing technical advice, Sepros Limited supports the health and productivity of animals and crops, contributing to the overall success of its customers in the agricultural industry. (sepros.co.ke)

There is a realistic opportunity for new Indian suppliers to engage with Sepros Limited, given the company's significant importation of pharmaceutical products from India. To capitalize on this opportunity, Indian exporters should focus on providing high-quality generic products that